Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4981-5003

  Fonseca Santos, Bruno ^a   Gremião, Maria Palmira Daflon ^a   Chorilli, Marlus ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Alzheimer s disease; Liquid crystals; Microemulsions; Nose to brain; Polymeric nanoparticles; Solid lipid nanocarriers; Targeted delivery

Indexed keywords

BETA ASARONE; CELL PENETRATING PEPTIDE; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CURCUMIN; CURCUMIN DERIVATIVE; DONEPEZIL; ETHOSOME; FIBROBLAST GROWTH FACTOR; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; HUPERZINE A; IODINE 125; LIPOSOME; MEMANTINE; NANOPARTICLE; NIOSOME; POLYMER; POLYMERIC NANOPARTICLE; POLYSORBATE 80; RIVASTIGMINE; SELEGILINE; SOLID LIPID NANOPARTICLE; TACRINE; TESTOSTERONE; THIOFLAVINE; TRANSFERSOME; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG; LIPID;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; LIQUID CRYSTAL; MICROEMULSION; NANOEMULSION; NANOTECHNOLOGY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; SYSTEMATIC REVIEW; VOMITING; AREA UNDER THE CURVE; BIOAVAILABILITY; BRAIN; CHEMISTRY; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; NANOMEDICINE; PROCEDURES; SOLUBILITY;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIQUID CRYSTALS; NANOMEDICINE; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYMERS; SOLUBILITY;

EID: 84939643638     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S87148     Document Type: Article

References (332)

1. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127.
2. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010; 362(4):329-344.
3. Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208-245.
4. Sood S, Jain K, Gowthamarajan K. Intranasal therapeutic strategies for management of Alzheimer’s disease. J Drug Target. 2014; 22(4):279-294.
5. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis. 2012;2012:728-983.
6. Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315-335.
7. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719-739.
8. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271(13):992-998.
9. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5): 379-397.
10. Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79(1):134-143.
11. Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet. 2007;46(7):599-612.
12. Arias JL, editor. Key aspects in nanotechnology and drug delivery. In: Nanotechnology and Drug Delivery. Volume 1: Nanoplatforms in Drug Delivery. Boca Raton: CRC Press; 2015:1-27.
13. Sharma S, Singh A. Nanotechnology based targeted drug delivery: current status and future prospects for drug development, drug discovery and development. In: Kapetanović IM, editor. Drug Discovery and Development: Present and Future. Croatia: InTech; 2011: 427-462.
14. Suri K, Wolfram J, Shen H, Ferrari M. Advances in nanotechnology-based drug delivery platforms and novel drug delivery systems. In: Singh M, Salnikova M, editors. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. San Diego: Academic Press; 2015:41-58.
15. Parveen S, Sahoo S. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet. 2006;45(10):965-988.
16. Orive G, Hernández RM, Rodríguez Gascón A, Domı́nguez-Gil A, Pedraz JL. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol. 2003;14(6):659-664.
17. Safari J, Zarnegar Z. Advanced drug delivery systems: nanotechnology of health design A review. Journal of Saudi Chemical Society. 2014; 18(2):85-99.
18. Betancourt T, Doiron A, Homan KA, Brannon-Peppas L. Controlled release and nanotechnology. In: de Villiers MM, Aramwit P, Kwon GS, editors. Nanotechnology in Drug Delivery. New York: Springer; 2009:283-312.
19. Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine. 2011;7(5):521-540.
20. Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer’s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis. 2008;13(2):199-223.
21. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2008;70(1):75-84.
22. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res. 2008;1200:159-168.
23. Zhang C, Wan X, Zheng X, et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease mice. Biomaterials. 2014;35(1):456-465.
24. Zhang C, Chen J, Feng C, et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer’s disease. Int J Pharm. 2014;461(1-2):192-202.
25. Brambilla D, Verpillot R, De Kimpe L, Taverna M, Le Droumaguet B, Andrieux K. Nanoparticles against Alzheimer’s disease: PEG-PACA nanoparticles are able to link the Aβ-peptide and influence its aggregation kinetic. J Biotechnol. 2010;150 Suppl:27.
26. Brambilla D, Verpillot R, Taverna M, et al. New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptide. Anal Chem. 2010;82(24):10083-10089.
27. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76(2):189-199.
28. Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci. 2012;47(1):6-15.
29. Amorim Cde M, Couto AG, Netz DJ, de Freitas RA, Bresolin TM. Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan. Nanomedicine. 2010;6(6):745-752.
30. Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target. 2013;21(3):300-311.
31. Sood S, Jain K, Gowthamarajan K. Curcumin-donepezil-loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer’s disease model. Alzheimers Dement. 2013;9(4):P299.
32. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394(1-2):179-185.
33. Frozza RL, Salbego C, Bernardi A, et al. Incorporation of resveratrol into lipid-core nanocapsules improves its cerebral bioavailability and reduces the Aβ-induced toxicity. Alzheimers Dement. 2011;7(4):S114.
34. Bondì ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine (Lond). 2009;5(1):25-32.
35. Patel PA, Patil SC, Kalaria DR, Kalia YN, Patravale VB. Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm. 2013;446(1-2):16-23.
36. Kakkar V, Muppu SK, Chopra K, Kaur IP. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm. 2013;85 (3 Pt A):339-345.
37. Yang ZZ, Zhang YQ, Wang ZZ, Wu K, Lou JN, Qi XR. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm. 2013;452(1-2): 344-354.
38. Ismail MF, Elmeshad AN, Salem NA. Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease. Int J Nanomedicine. 2013;8:393-406.
39. Kumaraswamy P, Sethuraman S, Krishnan UM. Liposomal delivery of a beta sheet blocker peptide for the treatment of Alzheimer’s disease. Alzheimers Dement. 2012;8(4 Suppl):P705.
40. Sancini G, Gregori M, Salvati E, et al. Functionalization with TAT-peptide enhances blood-brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptide. J Nanomed Nanotechnol. 2013;4(3).
41. Markoutsa E, Papadia K, Giannou AD, et al. Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies. Pharm Res. 2014;31(5):1275-1289.
42. Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem. 2014;80:175-183.
43. Lazar AN, Mourtas S, Youssef I, et al. Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine. 2013;9(5):712-721.
44. Mourtas S, Canovi M, Zona C, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials. 2011;32(6):1635-1645.
45. Mufamadi MS, Choonara YE, Kumar P, et al. Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm. 2013;448(1):267-281.
46. Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008; 8(3):287-297.
47. Mutlu NB, Değim Z, Yılmaz Ş, Eşsiz D, Nacar A. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm. 2011;37(7):775-789.
48. Degim Z, Mutlu NB, Yilmaz S, Eşsiz D, Nacar A. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie. 2010;65(1):32-40.
49. Ravouru N, Kondreddy P, Korakanchi D, Haritha M. Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Curr Drug Discov Technol. 2013;10(4):270-282.
50. Naik SR, Pilgaonkar VW, Panda VS. Evaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brain. Phytother Res. 2006; 20(11):1013-1016.
51. Jin Y, Wen J, Garg S, et al. Development of a novel niosomal system for oral delivery of Ginkgo biloba extract. Int J Nanomedicine. 2013;8:421-430.
52. Zhang LK, Xu RX, Jiang M, et al. Evaluation of brain-targeting of β-asarone microemulsion by intranasal administration. Chinese Traditional and Herbal Drugs. 2014;45(1):86-89.
53. Chaiyana W, Rades T, Okonogi S. Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata. Int J Pharm. 2013;452(1-2):201-210.
54. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008;22(2):116-124.
55. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-766.
56. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-356.
57. Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis. 2007;4(1):13-27.
58. Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430(7000):631-639.
59. Bush AI. The metal theory of Alzheimer’s disease. J Alzheimers Dis. 2013;33 Suppl 1:S277-S281.
60. Gouras GK, Beal MF. Metal chelator decreases Alzheimer β-amyloid plaques. Neuron. 2001;30(3):641-642.
61. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. 1999; 274(52):37111-37116.
62. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci. 1998;158(1):47-52.
63. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer’s disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 1999;274(33):23223-23228.
64. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 2001;30(3):665-676.
65. Bartus RT, Emerich DF. Cholinergic markers in Alzheimer disease. JAMA. 1999;282(23):2208-2209.
66. Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett. 1980;20(3):373-377.
67. Henke H, Lang W. Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer-type patients. Brain Res. 1983;267(2):281-291.
68. Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett. 1995;187(2): 79-82.
69. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CMC. Platelet phospholipase A2 activity in Alzheimer’s disease and mild cognitive impairment. J Neural Transm. 2004;111(5):591-601.
70. Gattaz WF, Talib LL, Schaeffer EL, Diniz BS, Forlenza OV. Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study. J Neural Transm. 2014;121(2):193-200.
71. Gattaz WF, Cairns NJ, Levy R, Förstl H, Braus DF, Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer’s disease. Eur Arch Psychiatry Clin Nuerosci. 1996;246(3):129-131.
72. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72(5):1858-1862.
73. Gong CX, Grundke-Iqbal I, Iqbal K. Targeting tau protein in Alzheimer’s disease. Drugs Aging. 2010;27(5):351-365.
74. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci. 2007;8(9):663-672.
75. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21(2):195-218.
76. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3(4):169-176.
77. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging. 2001;22(6):903-908.
78. Johnstone M, Gearing AJ, Miller KM. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol. 1999;93(1-2):182-193.
79. Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol. 2005;37(2):289-305.
80. Li C, Zhao R, Gao K, et al. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 2011;8(1):67-80.
81. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 2003; 27(3):325-355.
82. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer’s disease. Neurochem Int. 2001;39(5-6):333-340.
83. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292.
84. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-269.
85. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270-279.
86. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257-262.
87. Teng E, Ringman JM, Ross LK, et al; Alzheimer’s Disease Research Centers of California-Depression in Alzheimer’s Disease Investigators. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008;16(6):469-477.
88. Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002; 10(2):125-128.
89. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153.
90. Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol. 1987; 44(3):258-262.
91. Bird JM, Levy R, Jacoby RJ. Computed tomography in the elderly: changes over time in a normal population. Br J Psychiatry. 1986; 148:80-85.
92. Luxenberg JS, Haxby JV, Creasey H, Sundaram M, Rapoport SI. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration. Neurology. 1987;37(7):1135-1140.
93. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann Neurol. 2000;47(4):430-439.
94. Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58(8):1188-1196.
95. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007;64(7):1015-1020.
96. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3): 843-854.
97. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238-1248.
98. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68(7):501-508.
99. Dukart J, Kherif F, Mueller K, et al; Alzheimer’s Disease Neuroimaging Initiative. Generative FDG-PET and MRI model of aging and disease progression in Alzheimer’s disease. PLoS Comput Biol. 2013;9(4):e1002987.
100. Choi SR, Schneider JA, Bennett DA, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26(1):8-16.
101. Clark CM, Schneider JA, Bedell BJ, et al; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-283.
102. Lister-James J, Pontecorvo MJ, Clark C, et al. Florbetapir f-18: a histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med. 2011;41(4):300-304.
103. Johnson KA, Sperling RA, Gidicsin CM, et al; AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5 Suppl):S72-S83.
104. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319-329.
105. Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74(9):1206-1209.
106. Osimani A, Berger A, Friedman J, Porat-Katz BS, Abarbanel JM. Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects. J Geriatr Psychiatry Neurol. 2005; 18(1):33-38.
107. Vargas AP, Carod-Artal FJ, Del Negro MC, Rodrigues MP. [Dementia caused by neurosyphilis: clinical and neuropsychological follow-up of a patient]. Arq Neuropsiquiatr. 2000;58(2B):578-582.Portuguese.
108. Fleming KC, Adams AC, Petersen RC. Dementia: diagnosis and evaluation. Mayo Clin Proc. 1995;70(11):1093-1107.
109. Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Apolipoprotein E plasma level and genotype-/INS; risk of dementia in 76,000 individuals from the general population. J Neurol Sci. 2013;333:e342.
110. Goldman JS, Hahn SE, Catania JW, et al; American College of Medical Genetics and the National Society of Genetic Counselors. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011;13(6):597-605.
111. Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(1):35-47.
112. Härtig W, Paulke BR, Varga C, Seeger J, Harkany T, Kacza J. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer’s disease. Neurosci Lett. 2003;338(2):174-176.
113. Massoud F, Léger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579-588.
114. Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011;83(12):1403-1412.
115. Bentley P, Driver J, Dolan RJ. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. Brain. 2009;132(Pt 9):2356-2371.
116. Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin Drug Saf. 2009;8(1):89-109.
117. Lipton SA. The molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005;2(2):155-165.
118. Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. AJNR Am J Neuroradiol. 2001;22(10):1813-1824.
119. Molinuevo JL, Lladó A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias. Am J Alzheimers Dis Other Demen. 2005;20(2):77-85.
120. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry. 1999;14(1):3-47.
121. Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30(33):11246-11250.
122. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol. 2008;6(1):55-78.
123. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699-723.
124. Srinivasan M, Lahiri DK. Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis. Expert Opin Ther Targets. 2015;19(4): 471-487.
125. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. Scientific World Journal. 2012;2012:756357.
126. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(1):a006346.
127. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014;9:795-811.
128. Haque S, Md S, Alam MI, Sahni JK, Ali J, Baboota S. Nanostructure-based drug delivery systems for brain targeting. Drug Dev Ind Pharm. 2012;38(4):387-411.
129. Paolino D, Cosco D, Molinaro R, Celia C, Fresta M. Supramolecular devices to improve the treatment of brain diseases. Drug Discov Today. 2011;16(7-8):311-324.
130. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-420.
131. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci. 2007;31(5):249-261.
132. Oesterling BM, Gulati A, Joshi MD. Nanocarrier-based approaches for treatment and detection of Alzheimer’s disease. J Nanosci Nanotechnol. 2014;14(1):137-156.
133. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35-58.
134. Sainsbury F, Zeng B, Middelberg APJ. Towards designer nanoemulsions for precision delivery of therapeutics. Curr Opin Chem Eng. 2014;4:11-17.
135. Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damge C. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell. 1987;61(1-2): 69-76.
136. Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94(6): 1187-1195.
137. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998;5(6):415-441.
138. Kreuter J. Nanoparticles and nanocapsules-new dosage forms in the nanometer size range. Pharm Acta Helv. 1978;53(2):33-39.
139. Guterres SS, Alves MP, Pohlmann AR. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights. 2007;2:147-157.
140. Couvreur P, Barratt G, Fattal E, Vauthier C. Nanocapsule technology: a review. 2002;19(2):36.
141. Boudad H, Legrand P, Lebas G, Cheron M, Duchêne D, Ponchel G. Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm. 2001;218(1-2):113-124.
142. Souto EB, Severino P, Santana MHA. Preparação de nanopartículas poliméricas a partir da polimerização de monômeros: parte I [Preparation of polymeric nanoparticles by polymerization of monomers: part I]. Polímeros. 2012;22:96-100. Portuguese.
143. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. Carbohydr Polym. 2013;94(2):940-945.
144. Arora S, Gupta S, Narang RK, Budhiraja RD. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pylori. Sci Pharm. 2011;79(3):673-694.
145. Mainardes RM, Evangelista RC. Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J Microencapsul. 2005; 22(1):13-24.
146. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290(1-2):137-144.
147. Alshamsan A. Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles. Saudi Pharm J. 2014;22(3):219-222.
148. Mainardes RM, Gremião MPD. Nanoencapsulation and characterization of zidovudine on poly(L-lactide) and poly(L-lactide)-poly(ethylene glycol)-blend nanoparticles. J Nanosci Nanotechnol. 2012;12(11):8513-8521.
149. Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63(1):125-132.
150. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999;187(2):143-152.
151. Mazzarino L, Coche-Guérente L, Labbé P, Lemos-Senna E, Borsali R. On the mucoadhesive properties of chitosan-coated polycaprolactone nanoparticles loaded with curcumin using quartz crystal microbalance with dissipation monitoring. J Biomed Nanotechnol. 2014;10(5):787-794.
152. Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24(1):67-75.
153. Ali ME, Lamprecht A. Spray freeze drying for dry powder inhalation of nanoparticles. Eur J Pharm Biopharm. 2014;87(3):510-517.
154. Hu X, Guo Y, Wang L, Hua D, Hong Y, Li J. Coenzyme Q10 nanoparticles prepared by a supercritical fluid-based method. J Supercrit Fluids. 2011;57(1):66-72.
155. Chu KS, Hasan W, Rawal S, et al. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine. 2013;9(5):686-693.
156. Galloway AL, Murphy A, DeSimone JM, et al. Development of a nanoparticle-based influenza vaccine using the PRINT technology. Nanomedicine. 2013;9(4):523-531.
157. Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM. Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. J Control Release. 2007;121(1-2):10-18.
158. Jain KK. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener Dis. 2007;4(4):287-291.
159. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2012;161(2): 264-273.
160. Barbu E, Molnàr E, Tsibouklis J, Górecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv. 2009;6(6):553-565.
161. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006;310(1-2):213-219.
162. Soni S, Babbar AK, Sharma RK, Banerjee T, Maitra A. Pharmacoscintigraphic evaluation of polysorbate 80-coated chitosan nanoparticles for brain targeting. American Journal of Drug Delivery. 2005;3(3):205-212.
163. Jain KK. Nanoneurology. In: Applications of Biotechnology in Neurology. New York: Humana Press; 2013:283-294.
164. Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34(36):9171-9182.
165. Kuo YC, Hong TY. Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-moduline. Int J Pharm. 2014;465(1-2):132-142.
166. Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release. 2009;137(1):78-86.
167. Xin H, Sha X, Jiang X, et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles. Biomaterials. 2012;33(5):1673-1681.
168. Lu W, Tan YZ, Hu KL, Jiang XG. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int J Pharm. 2005;295(1-2): 247-260.
169. Mainardes RM, Urban MC, Cinto PO, Chaud MV, Evangelista RC, Gremião MP. Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Curr Drug Deliv. 2006;3(3):275-285.
170. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379(1):146-157.
171. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11(1):1-18.
172. Vila A, Gill H, McCallion O, Alonso MaJ. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Release. 2004;98(2):231-244.
173. Rocha S. Targeted drug delivery across the blood-brain barrier in Alzheimer’s disease. Curr Pharm Des. 2013;19(37):6635-6646.
174. Pawar D, Mangal S, Goswami R, Jaganathan KS. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm. 2013;85(3 Pt A): 550-559.
175. Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials. 2004;25(15):3065-3071.
176. Gao X, Tao W, Lu W, et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials. 2006;27(18):3482-3490.
177. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl. 1998;54:301-310.
178. Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann WM. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology. 1997;36(2):73-82.
179. Sinha M, Bhowmick P, Banerjee A, Chakrabarti S. Antioxidant role of amyloid β protein in cell-free and biological systems: implication for the pathogenesis of Alzheimer disease. Free Radic Biol Med. 2013;56:184-192.
180. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging. 2002;23(5):655-664.
181. Butterfield DA, Yatin SM, Varadarajan S, Koppal T. Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer’s disease. Methods Enzymol. 1999;309:746-768.
182. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998;15(9):1326-1331.
183. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556-1568.
184. Carvalho FC, Bruschi ML, Evangelista RC, Gremião MPD. Mucoadhesive drug delivery systems. Brazilian Journal of Pharmaceutical Sciences. 2010;46:1-17.
185. Carvalho FC, Chorilli M, Gremião MPD. Plataformas bio(muco) adesivas poliméricas baseadas em nanotecnologia para liberação controlada de fármacos-propriedades, metodologias e aplicações. Polímeros. 2014;24:203-213. Portuguese.
186. Cardile V, Frasca G, Rizza L, et al. Improved adhesion to mucosal cells of water-soluble chitosan tetraalkylammonium salts. Int J Pharm. 2008;362(1-2):88-92.
187. Henriksen I, Green KL, Smart JD, Smistad G, Karlsen J. Bioadhesion of hydrated chitosans: an in vitro and in vivo study. Int J Pharm. 1996;145(1-2):231-240.
188. Bodmer M, Vankan P, Dreier M, Kutz KW, Drewe J. Pharmacokinetics and metabolism of idebenone in healthy male subjects. Eur J Clin Pharmacol. 2009;65(5):493-501.
189. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54 Suppl 1: S131-S155.
190. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64 Suppl: 83-101.
191. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-184.
192. Kovačević AB, Müller RH, Savić SD, Vuleta GM, Keck CM. Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: preparation, characterization and physical stability investigation. Colloids Surf A Physicochem Eng Asp. 2014;444:15-25.
193. Lukowski G, Kasbohm J, Pflegel P, Illing A, Wulff H. Crystallographic investigation of cetylpalmitate solid lipid nanoparticles. Int J Pharm. 2000;196(2):201-205.
194. Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm. 2013;85(3 Pt A):488-502.
195. Xie S, Zhu L, Dong Z, et al. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces. 2011;83(2):382-387.
196. Kolenyak-Santos F, Garnero C, Oliveira RN, et al. Nanostructured lipid carriers as a strategy to improve the in vitro schistosomiasis activity of praziquantel. J Nanosci Nanotechnol. 2014;14:1-12.
197. Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335(1-2):167-175.
198. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces. 2011;88(1):483-489.
199. Vitorino C, Carvalho FA, Almeida AJ, Sousa JJ, Pais AA. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf B Biointerfaces. 2011;84(1):117-130.
200. Rahman Z, Zidan AS, Khan MA. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm. 2010;76(1):127-137.
201. Kumar R, Yasir M, Saraf SA, Gaur PK, Kumar Y, Singh AP. Glyceryl monostearate based nanoparticles of mefenamic acid: fabrication and in vitro characterization. Drug Invention Today. 2013;5(3):246-250.
202. Yasir M, Sara UVS. Preparation and optimization of haloperidol loaded solid lipid nanoparticles by Box-Behnken design. J Pharm Res. 2013;7(6):551-558.
203. Singh AP, Saraf SK, Saraf S. SLN approach for nose-to-brain delivery of alprazolam. Drug Deliv Transl Res. 2012;2(6):498-507.
204. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm. 2003;257(1-2):153-160.
205. Campardelli R, Cherain M, Perfetti C, et al. Lipid nanoparticles production by supercritical fluid assisted emulsion-diffusion. J Supercrit Fluids. 2013;82:34-40.
206. Acevedo-Morantes CY, Acevedo-Morantes MT, Suleiman-Rosado D, Ramírez-Vick JE. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Drug Deliv. 2013;20(8):338-348.
207. de Souza ALR, Andreani T, Nunes FM, et al. Loading of praziquantel in the crystal lattice of solid lipid nanoparticles. J Therm Anal Calorim. 2012;108(1):353-360.
208. de Souza ALR, Andreani T, de Oliveira RN, et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int J Pharm. 2014;463(1):31-37.
209. de Almeida AE, Souza ALR, Cassimiro DL, Gremião MPD, Ribeiro CA, Crespi MS. Thermal characterization of solid lipid nanoparticles containing praziquantel. J Therm Anal Calorim. 2012;108(1): 333-339.
210. Freitas C, Müllera RH. Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm. 1998;46(2):145-151.
211. Bourezg Z, Bourgeois S, Pressenda S, Shehada T, Fessi H. Redispersible lipid nanoparticles of spironolactone obtained by three drying methods. Colloids Surf A Physicochem Eng Asp. 2012;413:191-199.
212. Chavan SS, Ingle SG, Vavia PR. Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide. Drug Deliv Transl Res. 2013;3(5):402-408.
213. Martins S, Silva AC, Ferreira DC, Souto EB. Improving oral absorption of salmon calcitonin by trimyristin lipid nanoparticles. J Biomed Nanotechnol. 2009;5(1):76-83.
214. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers. Colloids Surf B Biointerfaces. 2012;94:68-72.
215. Hombach J, Bernkop-Schnürch A. Mucoadhesive drug delivery systems. Handb Exp Pharmacol. 2010;(197):251-266.
216. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:238-428.
217. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul. 1998;15(1):67-74.
218. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999;16(10): 1564-1569.
219. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674(1):171-174.
220. Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J Am Geriatr Soc. 1989;37(6):515-520.
221. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1): CD003119.
222. Marambaud P, Vingtdeux V, Giliberto L, et al. Resveratrol lowers beta-amyloid accumulation and deposition in vivo by controlling AMPK signaling. Alzheimers Dement. 2010;6(4):S406.
223. Bondi ML, Montana G, Craparo EF, et al. Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer’s disease: preparation, characterization and cytotoxicity studies. Curr Nanosci. 2009;5(1):26-32.
224. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. J Neural Transm. 2009;116(4):457-465.
225. Huang HC, Chang P, Dai XL, Jiang ZF. Protective effects of curcumin on amyloid-β-induced neuronal oxidative damage. Neurochem Res. 2012;37(7):1584-1597.
226. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res. 2004;75(6):742-750.
227. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892-5901.
228. Zhao LN, Chiu SW, Benoit J, Chew LY, Mu Y. The effect of curcumin on the stability of Aβ dimers. J Phys Chem B. 2012;116(25): 7428-7435.
229. Wang W, Zhu R, Xie Q, et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine. 2012;7:3667-3677.
230. Sun J, Bi C, Chan HM, Sun S, Zhang Q, Zheng Y. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf B Biointerfaces. 2013;111:367-375.
231. Wang P, Zhang L, Peng H, Li Y, Xiong J, Xu Z. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. Mater Sci Eng C Mater Biol Appl. 2013;33(8):4802-4808.
232. Vandita K, Shashi B, Santosh KG, Pal KI. Enhanced apoptotic effect of curcumin loaded solid lipid nanoparticles. Mol Pharm. 2012; 9(12):3411-3421.
233. Guri A, Gülseren I, Corredig M. Utilization of solid lipid nanoparticles for enhanced delivery of curcumin in cocultures of HT29-MTX and Caco-2 cells. Food Funct. 2013;4(9):1410-1419.
234. Ji H, Tang J, Li M, Ren J, Zheng N, Wu L. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin. Drug Deliv. Epub 2014 Jun 3:1-12.
235. Alex A, Paul W, Chacko AJ, Sharma CP. Enhanced delivery of lopinavir to the CNS using Compritol-based solid lipid nanoparticles. Ther Deliv. 2011;2(1):25-35.
236. Kuo YC, Liang CT. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials. 2011;32(12):3340-3350.
237. Martins S, Tho I, Reimold I, et al. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int J Pharm. 2012;439(1-2):49-62.
238. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm. 2002;54(3): 285-290.
239. Lasic DD. Novel applications of liposomes. Trends Biotechnol. 1998;16(7):307-321.
240. Gulati M, Grover M, Singh S, Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm. 1998;165(2):129-168.
241. Xu X, Khan MA, Burgess DJ. Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm. 2012;423(2): 410-418.
242. Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. Application of response surface methodology in development of sirolimus liposomes prepared by thin film hydration technique. Bioimpacts. 2013;3(2):75-81.
243. Elzainy AA, Gu X, Simons FE, Simons KJ. Hydroxyzine-and cetirizine-loaded liposomes: effect of duration of thin film hydration, freeze-thawing, and changing buffer pH on encapsulation and stability. Drug Dev Ind Pharm. 2005;31(3):281-291.
244. Li X, Chen D, Le C, et al. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int J Nanomedicine. 2011;6:3151-3162.
245. Chorilli M, Calixto G, Rimério TC, Scarpa MV. Caffeine encapsulated in small unilamellar liposomes: characerization and in vitro release profile. J Dispers Sci Technol. 2013;34(10):1465-1470.
246. Chorilli M, Rimério TC, De Oliveira AG, Scarpa MV. Study of liposomes stability containing soy phosphatidylcholine and hydrogenated soy phosphatydylcholine adding or not cholesterol by turbidity method. Latin American Journal of Pharmacy. 2007;26(1):31-37.
247. Chorilli M, Rimério TC, De Oliveira AG, Scarpa MV. Obtaining and characterization of small unilamellar liposomes containing caffeine. Latin American Journal of Pharmacy. 2007;26(5):715-722.
248. Barichello JM, Kizuki S, Tagami T, et al. Agitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomes. Int J Pharm. 2012;430(1-2):359-365.
249. Hadian Z, Sahari MA, Moghimi HR, Barzegar M. Formulation, characterization and optimization of liposomes containing eicosapentaenoic and docosahexaenoic acids; a methodology approach. Iran J Pharm Res. 2014;13(2):393-404.
250. Cho NJ, Hwang LY, Solandt JJR, Frank CW. Comparison of extruded and sonicated vesicles for planar bilayer self-assembly. Materials. 2013;6(8):3294-3308.
251. Isailović BD, Kostić IT, Zvonar A, et al. Resveratrol loaded liposomes produced by different techniques. Innovative Food Science and Emerging Technologies. 2013;19:181-189.
252. Curić A, Reul R, Möschwitzer J, Fricker G. Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experiments. Int J Pharm. 2013;448(1):189-197.
253. Ninomiya K, Kawabata S, Tashita H, Shimizu N. Ultrasound-mediated drug delivery using liposomes modified with a thermosensitive polymer. Ultrason Sonochem. 2014;21(1):310-316.
254. Mourão SC, Costa PI, Salgado HR, Gremião MP. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm. 2005; 295(1-2):157-162.
255. Ye P, Zhang W, Yang T, et al. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Int J Nanomedicine. 2014;9:2167-2178.
256. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta. 1979;557(1):9-23.
257. Jousma H, Talsma H, Spies F, Joosten JGH, Junginger HE, Crommelin DJA. Characterization of liposomes. The influence of extrusion of multilamellar vesicles through polycarbonate membranes on particle size, particle size distribution and number of bilayers. Int J Pharm. 1987;35(3):263-274.
258. Berger N, Sachse A, Bender J, Schubert R, Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm. 2001;223(1-2):55-68.
259. Pupo E, Padrón A, Santana E, et al. Preparation of plasmid DNA-containing liposomes using a high-pressure homogenization-extrusion technique. J Control Release. 2005;104(2):379-396.
260. Barnadas-Rodrı́guez R, Sabés M. Factors involved in the production of liposomes with a high-pressure homogenizer. Int J Pharm. 2001; 213(1-2):175-186.
261. Brandl M, Bachmann D, Drechsler M, Bauer KH. Liposome preparation by a new high pressure homogenizer Gaulin Micron Lab 40. Drug Dev Ind Pharm. 1990;16(14):2167-2191.
262. Chung SK, Shin GH, Jung MK, Hwang IC, Park HJ. Factors influencing the physicochemical characteristics of cationic polymer-coated liposomes prepared by high-pressure homogenization. Colloids Surf A Physicochem Eng Asp. 2014;454:8-15.
263. Szoka F Jr, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A. 1978;75(9):4194-4198.
264. Cortesi R, Esposito E, Gambarin S, Telloli P, Menegatti E, Nastruzzi C. Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. J Microencapsul. 1999;16(2):251-256.
265. Chen G, Li D, Jin Y, et al. Deformable liposomes by reverse-phase evaporation method for an enhanced skin delivery of (+)-catechin. Drug Dev Ind Pharm. 2013;40(2):260-265.
266. García-Jimeno S, Escribano E, Queralt J, Estelrich J. Magnetoliposomes prepared by reverse-phase followed by sequential extrusion: Characterization and possibilities in the treatment of inflammation. Int J Pharm. 2011;405(1-2):181-187.
267. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269(1):1-14.
268. Malmsten M. Liposomes. In: Surfactants and Polymers in Drug Delivery. CRC Press; 2002.
269. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001;228(1-2):43-52.
270. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophy Acta. 1992;1104(1):226-232.
271. Arora S, Lamba HS, Tiwari R. Dermal delivery of drugs using different vesicular carriers: a comparative review. Asian Journal of Pharmaceutics. 2012;6(4):237-244.
272. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65(3):403-418.
273. Saroj S, Baby DA, Sabitha M. Current trends in lipid based delivery systems and its applications in drug delivery. Asian Journal of Pharmaceutical and Clinical Research. 2012;5(Suppl 3):4-9.
274. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. Neuro Rx. 2005;2(1):99-107.
275. De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: a strategy to overcome blood-brain barrier. Curr Drug Metab. 2012;13(1):61-69.
276. Loureiro JA, Gomes B, Coelho MAN, do Carmo Pereira M, Rocha S. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. Nanomedicine (Lond). 2014;9(5):709-722.
277. Murugan K, Choonara YE, Kumar P, Bijukumar D, du Toit LC, Pillay V. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int J Nanomedicine. 2015;10:2191-2206.
278. Herda LM, Polo E, Kelly PM, Rocks L, Hudecz D, Dawson KA. Designing the future of nanomedicine: current barriers to targeted brain therapeutics. Eur J Nanomed. 2014;6(3):127-139.
279. Lai F, Fadda AM, Sinico C. Liposomes for brain delivery. Expert Opin Drug Deliv. 2013;10(7):1003-1022.
280. Salvati E, Re F, Sesana S, et al. Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model. Int J Nanomedicine. 2013;8:1749-1758.
281. Hashizume R, Frey WH II. Intranasal delivery-a new therapeutic approach for brain tumors. US Neurol. 2008;4(2):43-44.
282. Tayebati SK, Nwankwo IE, Amenta F. Intranasal drug delivery to the central nervous system: present status and future outlook. Curr Pharm Des. 2013;19(3):510-526.
283. Shah L, Yadav S, Amiji M. Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv Transl Res. 2013;3(4):336-351.
284. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev. 2008;(4):CD004514.
285. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;(1):CD003120.
286. Ezrahi S, Aserin A, Garti N. Aggregation behavior in one-phase (Winsor IV) microemulsion systems. In: Kumar P, Mittal KL, editors. Handbook of Microemulsion Science and Technology. New York: Marcel Dekker, Inc; 1999:195-240.
287. Malmsten M. Surfactants and Polymers in Drug Delivery. New York: CRC Press; 2002.
288. Langevin D. Microemulsions. Acc Chem Res. 1988;21(7):255-260.
289. Manoharan C, Basarkar A, Singh J. Various pharmaceutical disperse systems. In: Kulshreshtha AK, Singh ON, Wall GM, editors. Pharmaceutical Suspensions: From Formulation Development to Manufacturing. New York: Springer; 2010:1-37.
290. McClements DJ. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter. 2012;8(6):1719-1729.
291. Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM. Nanoemulsions: formation, structure, and physical properties. J Phys Condens Matter. 2006;18:R635.
292. Urban MCC, Mainardes RM, Gremião MPD. Development and validation of HPLC method for analysis of dexamethasone acetate in microemulsions. Brazilian Journal of Pharmaceutical Sciences. 2009;45:87-92.
293. Carvalho FC, Barbi MdS, Gremião MPD. LC evaluation of in vitro release of AZT from microemulsions. Chromatographia. 2009; 69(2):207-211.
294. Carvalho FC, Sarmento VH, Chiavacci LA, Barbi MS, Gremião MP. Development and in vitro evaluation of surfactant systems for controlled release of zidovudine. J Pharm Sci. 2010;99(5):2367-2374.
295. Macedo AS, Quelhas S, Silva AM, Souto EB. Nanoemulsions for delivery of flavonoids: formulation and in vitro release of rutin as model drug. Pharm Dev Technol. 2014;19(6):677-680.
296. Dias DDO, Colombo M, Kelmann RG, et al. Optimization of Copaiba oil-based nanoemulsions obtained by different preparation methods. Ind Crops Prod. 2014;59:154-162.
297. Lee L, Hancocks R, Noble I, Norton IT. Production of water-in-oil nanoemulsions using high pressure homogenisation: a study on droplet break-up. J Food Eng. 2014;131:33-37.
298. Jo YJ, Kwon YJ. Characterization of β-carotene nanoemulsions prepared by microfluidization technique. Food Sci Biotechnol. 2014; 23(1):107-113.
299. da Silva GB, Scarpa MV, Rossanezi G, do Egito ES, de Oliveira AG. Development and characterization of biocompatible isotropic and anisotropic oil-in-water colloidal dispersions as a new delivery system for methyl dihydrojasmonate antitumor drug. Int J Nanomedicine. 2014;9:867-876.
300. Sood S, Jain K, Gowthamarajan K. Delivery of neuroprotective polyphenol to the brain via an intranasal route for management of Alzheimer’s disease. Alzheimers Dement. 2013;9(4):P299.
301. Shi J, Cong W, Wang Y, Liu Q, Luo G. Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer’s disease. Drug Dev Ind Pharm. 2012;38(6):752-761.
302. Malmsten M. Liquid crystals. In: Surfactants and Polymers in Drug Delivery. CRC Press; 2002.
303. Kato T, editor. Liquid Crystalline Functional Assemblies and Their Supramolecular Structures. New York: Springer; 2008.
304. Mueller-Goymann CC, Frank SG. Interaction of lidocaine and lidocaine-HCl with the liquid crystal structure of topical preparations. Int J Pharm. 1986;29(2-3):147-159.
305. Malmsten M. Phase transformations in self-assembly systems for drug delivery applications. J Dispers Sci Technol. 2007;28(1):63-72.
306. Garti N, Libster D, Aserin A. Lipid polymorphism in lyotropic liquid crystals for triggered release of bioactives. Food Funct. 2012; 3(7):700-713.
307. Kaasgaard T, Drummond CJ. Ordered 2-D and 3-D nanostructured amphiphile self-assembly materials stable in excess solvent. Phys Chem Chem Phys. 2006;8(43):4957-4975.
308. Drummond CJ, Fong C. Surfactant self-assembly objects as novel drug delivery vehicles. Curr Opin Colloid Interface Sci. 1999;4(6): 449-456.
309. Yaghmur A, Glatter O. Characterization and potential applications of nanostructured aqueous dispersions. Adv Colloid Interface Sci. 2009;147-148:333-342.
310. Carvalho FC, Campos ML, Peccinini RG, Gremião MPD. Nasal administration of liquid crystal precursor mucoadhesive vehicle as an alternative antiretroviral therapy. Eur J Pharm Biopharm. 2013;84(1):219-227.
311. Carvalho FC, Barbi MS, Sarmento VH, Chiavacci LA, Netto FM, Gremião MP. Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties. J Pharm Pharmacol. 2010;62(4):430-439.
312. Shah JC, Sadhale Y, Chilukuri DM. Cubic phase gels as drug delivery systems. Adv Drug Deliv Rev. 2001;47(2-3):229-250.
313. Nielsen LS, Schubert L, Hansen J. Bioadhesive drug delivery systems. I. Characterisation of mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl monolinoleate. Eur J Pharm Sci. 1998;6(3):231-239.
314. Bruschi ML, de Freitas O, Lara EH, Panzeri H, Gremião MP, Jones DS. Precursor system of liquid crystalline phase containing propolis microparticles for the treatment of periodontal disease: development and characterization. Drug Dev Ind Pharm. 2008;34(3): 267-278.
315. Spicer PT, Small WB II, Small WB, Lynch ML, Burns JL. Dry powder precursors of cubic liquid crystalline nanoparticles (cubosomes). J Nanopart Res. 2002;4(4):297-311.
316. Ren X, Svirskis D, Alany RG, Zargar-Shoshtari S, Wu Z. In-situ phase transition from microemulsion to liquid crystal with the potential of prolonged parenteral drug delivery. Int J Pharm. 2012;431(1-2): 130-137.
317. Chan J, Maghraby GM, Craig JP, Alany RG. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm. 2007;328(1):65-71.
318. Ahmad MZ, Ahmad J, Amin S, et al. Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2014;13(8): 1315-1324.
319. Kumar N, Kumar R, editors. Nanomedicine for neurological disorders. In: Nanotechnology and Nanomaterials in the Treatment of Life-Threatening Diseases. Oxford: William Andrew Publishing; 2014:109-175.
320. Miyake MM, Bleier BS. The blood-brain barrier and nasal drug delivery to the central nervous system. Am J Rhinol Allergy. 2015;29(2): 124-127.
321. Wong YC, Zuo Z. Intranasal delivery-modification of drug metabolism and brain disposition. Pharm Res. 2010;27(7):1208-1223.
322. Ligade PC, Jadhav KR, Kadam VJ. Brain drug delivery system: an overview. Curr Drug ther. 2010;5(2):105-110.
323. Pathan SA, Iqbal Z, Zaidi SM, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul. 2009;3(1):71-89.
324. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21(2):75-86.
325. Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014;189:133-140.
326. Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010;40(5):385-403.
327. Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2015;55:613-631.
328. Gaillard PJ, Visser CC, Appeldoorn CC, Rip J. Targeted blood-to-brain drug deliver-10 key development criteria. Curr Pharm Biotechnol. 2012;13(12):2328-2339.
329. Kozlovskaya L, Stepensky D. Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems. J Control Release. 2013;171(1):17-23.
330. Gulati M, Chopra DS, Singh SK, Saluja V, Pathak P, Bansal P. Patents on brain permeable nanoparticles. Recent Pat CNS Drug Discov. 2013;8(3):220-234.
331. Spuch C, Saida O, Navarro C. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat Drug Deliv Formul. 2012;6(1):2-18.
332. Fan AM, Alexeeff G. Nanotechnology and nanomaterials: toxicology, risk assessment, and regulations. J Nanosci Nanotechnol. 2010;10(12):8646-8657.